The University of Chicago Header Logo

Connection

Koen Van Besien to Graft vs Host Disease

Back to Details
This is a "connection" page, showing publications Koen Van Besien has written about Graft vs Host Disease.
Koen Van Besien
Connection Strength
13.263
Graft vs Host Disease
  1. Haplo-cord transplant. Realizing the potential of umbilical cord blood grafts. - A review of techniques and analysis of outcomes. Leuk Lymphoma. 2024 Oct; 65(10):1384-1397.
    View in: PubMed
    Score: 0.783
  2. Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (ESKD). Bone Marrow Transplant. 2023 07; 58(7):835-838.
    View in: PubMed
    Score: 0.720
  3. Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell-Depleted Stem Cell Transplantation. Transplant Cell Ther. 2022 09; 28(9):618.e1-618.e10.
    View in: PubMed
    Score: 0.680
  4. Allogeneic transplant graft source - conditioning - GVHD prophylaxis: don't mix and match! Leuk Lymphoma. 2022 01; 63(1):7-9.
    View in: PubMed
    Score: 0.654
  5. Impact of alemtuzumab dosing and low-dose total body irradiation on cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2020 12; 61(12):3024-3026.
    View in: PubMed
    Score: 0.595
  6. Cord blood transplants supported by unrelated donor CD34+ progenitor cells. Bone Marrow Transplant. 2020 12; 55(12):2298-2307.
    View in: PubMed
    Score: 0.591
  7. Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies. Biol Blood Marrow Transplant. 2020 04; 26(4):789-797.
    View in: PubMed
    Score: 0.573
  8. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867.
    View in: PubMed
    Score: 0.553
  9. Tocilizumab, in search for a role in acute GVHD. Leuk Lymphoma. 2019 09; 60(9):2101-2103.
    View in: PubMed
    Score: 0.553
  10. Earlier may be better: the role of extracorporeal photopheresis (ECP) as prevention of GVHD after allogeneic transplant. Leuk Lymphoma. 2018 02; 59(2):272-273.
    View in: PubMed
    Score: 0.486
  11. Against the odds: haplo-cord grafts protect from GvHD and relapse. Bone Marrow Transplant. 2017 12; 52(12):1590-1591.
    View in: PubMed
    Score: 0.481
  12. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Mar; 22(3):456-61.
    View in: PubMed
    Score: 0.430
  13. Allografting versus Autografting for Follicular Lymphoma: An Ongoing Conundrum. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2035-2036.
    View in: PubMed
    Score: 0.428
  14. Antithymocyte globulin for graft-versus-host disease prophylaxis: mistakenly maligned. Leuk Lymphoma. 2015 Apr; 56(4):841-2.
    View in: PubMed
    Score: 0.408
  15. Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. Hematology Am Soc Hematol Educ Program. 2013; 2013:56-62.
    View in: PubMed
    Score: 0.353
  16. cGVHD of skin: simple tools, great advances. Blood. 2012 Sep 27; 120(13):2537-8.
    View in: PubMed
    Score: 0.347
  17. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011 Dec 08; 118(24):6438-45.
    View in: PubMed
    Score: 0.324
  18. Alemtuzumab in allogeneic hematopoetic stem cell transplantation. Expert Opin Biol Ther. 2011 Aug; 11(8):1099-111.
    View in: PubMed
    Score: 0.318
  19. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):610-7.
    View in: PubMed
    Score: 0.274
  20. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone Marrow Transplant. 2008 Mar; 41(6):505-13.
    View in: PubMed
    Score: 0.248
  21. Standardizing chronic graft-versus-host disease. Future Oncol. 2006 Aug; 2(4):459-62.
    View in: PubMed
    Score: 0.226
  22. Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors). Transplant Cell Ther. 2024 Nov; 30(11):1100.e1-1100.e11.
    View in: PubMed
    Score: 0.198
  23. Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. Biol Blood Marrow Transplant. 2019 03; 25(3):466-473.
    View in: PubMed
    Score: 0.132
  24. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 02; 24(2):359-365.
    View in: PubMed
    Score: 0.124
  25. Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell transplant recipients and donors. Bone Marrow Transplant. 2017 Dec; 52(12):1643-1650.
    View in: PubMed
    Score: 0.123
  26. The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. Transplantation. 2017 Jan; 101(1):e34-e38.
    View in: PubMed
    Score: 0.116
  27. Haplo-cord transplant: HLA-matching determines graft dominance. Leuk Lymphoma. 2017 06; 58(6):1512-1514.
    View in: PubMed
    Score: 0.115
  28. Haploidentical cord transplantation-The best of both worlds. Semin Hematol. 2016 10; 53(4):257-266.
    View in: PubMed
    Score: 0.113
  29. Cord blood chimerism and relapse after haplo-cord transplantation. Leuk Lymphoma. 2017 02; 58(2):288-297.
    View in: PubMed
    Score: 0.112
  30. Early human herpes virus type 6 reactivation in umbilical cord blood allogeneic stem cell transplantation. Leuk Lymphoma. 2016 11; 57(11):2555-9.
    View in: PubMed
    Score: 0.110
  31. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clin Lymphoma Myeloma Leuk. 2016 May; 16(5):297-303.
    View in: PubMed
    Score: 0.110
  32. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43.
    View in: PubMed
    Score: 0.110
  33. Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors? Curr Hematol Malig Rep. 2015 Mar; 10(1):1-7.
    View in: PubMed
    Score: 0.103
  34. Microchimerism and allogeneic transplantation: we need the proof in the pudding. Chimerism. 2013 Jul-Sep; 4(3):109-10.
    View in: PubMed
    Score: 0.090
  35. Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. Leuk Lymphoma. 2012 Jan; 53(1):158-9.
    View in: PubMed
    Score: 0.081
  36. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1775-82.
    View in: PubMed
    Score: 0.079
  37. Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011 Jan; 17(1):124-32.
    View in: PubMed
    Score: 0.074
  38. Stem-cell transplantation for sickle cell disease. N Engl J Med. 2010 Mar 11; 362(10):955; author reply 956.
    View in: PubMed
    Score: 0.073
  39. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010 Jun; 45(6):1068-76.
    View in: PubMed
    Score: 0.071
  40. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009 Nov; 50(11):1809-17.
    View in: PubMed
    Score: 0.071
  41. Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):554-63.
    View in: PubMed
    Score: 0.068
  42. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009 May 21; 113(21):5074-82.
    View in: PubMed
    Score: 0.068
  43. Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. Hematology Am Soc Hematol Educ Program. 2009; 610-8.
    View in: PubMed
    Score: 0.067
  44. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1209-16.
    View in: PubMed
    Score: 0.066
  45. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008 Oct 01; 112(7):2667-74.
    View in: PubMed
    Score: 0.065
  46. Chimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplant. 2007 Jul; 40(2):181.
    View in: PubMed
    Score: 0.060
  47. Severe intestinal graft-versus-host disease following autologous stem cell transplantation. Bone Marrow Transplant. 2006 Sep; 38(5):391-2.
    View in: PubMed
    Score: 0.057
  48. Order of patient entry influences outcome for metastatic renal cell cancer after non-myeloablative allogeneic stem cell transplantation. Br J Haematol. 2006 Mar; 132(6):747-54.
    View in: PubMed
    Score: 0.055
  49. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
    View in: PubMed
    Score: 0.053
  50. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005 May; 35(10):965-70.
    View in: PubMed
    Score: 0.052
  51. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Sep; 32(5):471-6.
    View in: PubMed
    Score: 0.046
  52. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies. Bone Marrow Transplant. 2003 Jul; 32(1):9-13.
    View in: PubMed
    Score: 0.046
  53. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 2001 Sep 15; 98(6):1695-700.
    View in: PubMed
    Score: 0.040
  54. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplant. 2000 Aug; 26(4):445-9.
    View in: PubMed
    Score: 0.037
  55. Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant. 2000; 6(2A):190-7.
    View in: PubMed
    Score: 0.036
  56. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999 Oct; 24(7):763-8.
    View in: PubMed
    Score: 0.035
  57. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999 Aug 15; 94(4):1465-70.
    View in: PubMed
    Score: 0.035
  58. Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2019 07; 54(7):1058-1066.
    View in: PubMed
    Score: 0.033
  59. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004.
    View in: PubMed
    Score: 0.031
  60. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant. 1997 Aug; 3(3):150-6.
    View in: PubMed
    Score: 0.030
  61. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May; 97(2):466-73.
    View in: PubMed
    Score: 0.030
  62. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol. 1997 Feb; 15(2):667-73.
    View in: PubMed
    Score: 0.029
  63. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med. 1996 Mar; 100(3):299-307.
    View in: PubMed
    Score: 0.027
  64. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995 Oct 01; 86(7):2842-8.
    View in: PubMed
    Score: 0.027
  65. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Clin Adv Hematol Oncol. 2014 Sep; 12(9):565-73.
    View in: PubMed
    Score: 0.025
  66. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009 Jan; 15(1):109-17.
    View in: PubMed
    Score: 0.017
  67. Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91.
    View in: PubMed
    Score: 0.017
  68. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23.
    View in: PubMed
    Score: 0.012
  69. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Mar 01; 97(5):1242-7.
    View in: PubMed
    Score: 0.011
  70. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant. 2000 Aug; 26(3):333-8.
    View in: PubMed
    Score: 0.009
  71. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32.
    View in: PubMed
    Score: 0.009
  72. The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 1997 Jun; 3(2):76-82.
    View in: PubMed
    Score: 0.007
  73. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997 Mar; 19(5):455-60.
    View in: PubMed
    Score: 0.007
  74. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation. 1996 Dec 27; 62(12):1806-10.
    View in: PubMed
    Score: 0.007
  75. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995 Dec 01; 86(11):4337-43.
    View in: PubMed
    Score: 0.007
  76. Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation. Cytokines Mol Ther. 1995 Jun; 1(2):115-22.
    View in: PubMed
    Score: 0.007
  77. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995 Mar 15; 85(6):1659-65.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.